1 research outputs found
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡ/ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘, Π²ΡΠ·Π²Π°Π½Π½ΡΠΌ Π²ΠΈΡΡΡΠ°ΠΌΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² 1β6, Π² ΡΡΡΠΈΠ½Π½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ Π² Π ΠΎΡΡΠΈΠΈ
Background: Glecaprevir/pibrentasvir (GLE/PIB) is the first pangenotypic ribavirin-free regimen allowing for treatment duration as short as 8 weeks for the majority of patients with chronic hepatitis C (CHC) genotypes (GT) 1 to 6. The results of clinical trials showed good tolerability of GLE/PIB and high virologic response rate (mostly >95%) among different patient populations. The main objective of this study was to determine how the efficacy and safety of GLE/PIB translates into real-world clinical settings in Russia.Materials and Methods: This was a prospective, multicenter observational study in patients with CHC who received the GLE/PIB regimen. The treatment regimen was prescribed by a physician in accordance with all applicable requirements before the enrollment in the study. Patients were observed for the duration of GLE/PIB therapy and at least for up to 12 weeks after the treatment completion. Real-world data were collected in patient records. Follow-up visits, procedures, and diagnostic methods followed physiciansβ routine clinical practice.Results: Overall 161 patients were enrolled in the study in 11 study sites of them 128 patients had sufficient follow-up data to assess sustained virological response 12 weeks [i.e. β₯70 days] after the end of treatment with GLE/PIB (SVR12). Overall, 127 out of 128 patients (99.2%) achieved SVR12. Depending on treatment duration the following SVR12 rates were achieved: 98.7% in 8-week group (75/76), 100% in 12-week group (49/49) and 100% in 16-week group (3/3). One patient failed to achieve SVR, the exact reasons of failure couldnβt be established by the Investigator.Since only one patient didnβt achieve primary endpoint the following SVR12 rates were achieved in different subpopulations: 91.7% in patients with GT2 (11/12); 98.9% in non-cirrhotic patients (88/89); 99.1% in treatment-naΓ―ve patients (113/114); 99.1% in patients without HIV co-infection (116/117); 99.2% in patients younger than 65 years (120/121).On the other hand, SVR12 was achieved by all patients (100%) in the following subpopulations: patients with GT3 (n=76), GT1a (n=5), GT1b (n=29) and other GTs (n=6); cirrhotic patients (n=36) and those with unknown cirrhosis status (n=3); treatment-experienced patients (n=14); HIV/HCV co-infected patients (n=11); patients older than 65 years (n=7); and drug users (n=10).No clinically significant abnormalities in the key laboratory parameters were noted during the study. On contrary, the overall improvement of the liver enzymes was observed at SVR12 Visit. There were 3 patients with 3 adverse events (AEs): 2 cases were mild (cough and rash), and 1 case was severe and evaluated as a serious AE (hepatic decompensation). Hepatic decompensation led to the patient withdrawal from the study; this serious AE was preceded by 2 months of daily alcohol consumption and in the investigatorβs opinion was not related to GLE/PIB intake. Of all AEs only rash was related to GLE/PIB administration according to investigatorβs opinion.Conclusion: GLE/PIB has proven to be a highly effective treatment regimen in the routine clinical practice in patients with all hepatitis C virus genotypes, including those with GT3 and compensated liver cirrhosis. SVR12 rates demonstrated in this study are fully consistent with the previously published data. The regimen was well tolerated by patients.Π¦Π΅Π»Ρ: ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ° β ΡΡΠΎ ΠΏΠ΅ΡΠ²Π°Ρ ΠΏΠ°Π½Π³Π΅Π½ΠΎΡΠΈΠΏΠΈΠΏΠ½Π°Ρ ΡΡ
Π΅ΠΌΠ° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘, Π½Π΅ ΡΡΠ΅Π±ΡΡΡΠ°Ρ Π΄ΠΎΠ±Π°Π²Π»Π΅Π½ΠΈΡ ΡΠΈΠ±Π°Π²ΠΈΡΠΈΠ½Π° ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ°Ρ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡ 8-Π½Π΅Π΄Π΅Π»ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠ°ΠΌΠΈ 1β6. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ Ρ
ΠΎΡΠΎΡΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ° ΠΈ Π²ΡΡΠΎΠΊΡΡ ΡΠ°ΡΡΠΎΡΡ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° (>95%) Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΡΠ΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°Π»Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ Π² Π ΠΎΡΡΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π΄Π°Π½Π½ΠΎΠ΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΌΠ½ΠΎΠ³ΠΎΡΠ΅Π½ΡΡΠΎΠ²ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ°. Π’Π΅ΡΠ°ΠΏΠΈΡ Π½Π°Π·Π½Π°ΡΠ°Π»Π°ΡΡ Π»Π΅ΡΠ°ΡΠΈΠΌ Π²ΡΠ°ΡΠΎΠΌ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ ΡΠΎ Π²ΡΠ΅ΠΌΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΠΈΠΌΡΠΌΠΈ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ Π΄ΠΎ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΠ°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΎΡΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠ΅ΠΉ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ° ΠΈ ΠΏΠΎ ΠΌΠ΅Π½ΡΡΠ΅ΠΉ ΠΌΠ΅ΡΠ΅ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 12 Π½Π΅Π΄Π΅Π»Ρ ΠΏΠΎΡΠ»Π΅ Π΅Π΅ Π·Π°Π²Π΅ΡΡΠ΅Π½ΠΈΡ. ΠΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΡΠΎΠ±ΠΈΡΠ°Π»Π°ΡΡ ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π·Π°ΠΏΠΈΡΠ΅ΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠΈΠ·ΠΈΡΡ, ΠΏΡΠΎΡΠ΅Π΄ΡΡΡ ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°Π½ΠΈΠΏΡΠ»ΡΡΠΈΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΏΡΠΈΠ½ΡΡΠΎΠΉ ΡΡΡΠΈΠ½Π½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΎΠΉ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π² 11 ΡΠ΅Π½ΡΡΠ°Ρ
Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ» Π²ΠΊΠ»ΡΡΠ΅Π½ 161 ΠΏΠ°ΡΠΈΠ΅Π½Ρ, ΠΈΠ· Π½ΠΈΡ
Ρ 128 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±ΡΠ»ΠΈ ΡΠΎΠ±ΡΠ°Π½Ρ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ (Ρ.Π΅. β₯70 Π΄Π½Π΅ΠΉ) ΠΏΠΎΡΠ»Π΅ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠ΅ΠΉ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ°. Π ΠΎΠ±ΡΠ΅ΠΉ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ Ρ 127 ΠΈΠ· 128 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (99,2%) Π±ΡΠ» Π΄ΠΎΡΡΠΈΠ³Π½ΡΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΡΠΉ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅Ρ ΠΊΠΈΠΉ ΠΎΡΠ²Π΅Ρ ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ. Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠ΅ΠΉ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ° ΡΠ°ΡΡΠΎΡΠ° ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Π±ΡΠ»Π° ΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ: 8 Π½Π΅Π΄Π΅Π»Ρ β 98,7% (75/76), 12 Π½Π΅Π΄Π΅Π»Ρ β 100% (49/49) ΠΈ 16 Π½Π΅Π΄Π΅Π»Ρ β 100% (3/3). Π£ 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π½Π΅ ΡΠ΄Π°Π»ΠΎΡΡ Π΄ΠΎΡΡΠΈΡΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ, ΡΠΎΡΠ½ΡΠ΅ ΠΏΡΠΈΡΠΈΠ½Ρ Π½Π΅ΡΠ΄Π°ΡΠΈ Π½Π΅ Π±ΡΠ»ΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ.ΠΠΎΡΠΊΠΎΠ»ΡΠΊΡ 1 ΠΏΠ°ΡΠΈΠ΅Π½Ρ Π½Π΅ Π΄ΠΎΡΡΠΈΠ³ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΡΠΎΡΠΊΠΈ, Π² ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊ ΠΊΠΎΡΠΎΡΡΠΌ ΠΎΠ½ ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ°Π», Π±ΡΠ»Π° ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΡΠ»Π΅Π΄ΡΡΡΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ: 91,7% ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ 2 (11/12); 98,9% ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΡΠΈΡΡΠΎΠ·Π° (88/89); 99,1% ΡΡΠ΅Π΄ΠΈ ΡΠ°Π½Π΅Π΅ Π½Π΅ Π»Π΅ΡΠ΅Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (113/114); 99,1% ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· Π²ΠΈΡΡΡΠ° ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠΈΡΠΈΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (116/117); 99,2% ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΌΠ»Π°Π΄ΡΠ΅ 65 Π»Π΅Ρ (120/121) ΠΈ 99,2% ΡΡΠ΅Π΄ΠΈ Π½Π΅ ΡΠΏΠΎΡΡΠ΅Π±Π»ΡΠ²ΡΠΈΡ
Π½Π°ΡΠΊΠΎΡΠΈΠΊΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (117/118).Π‘ Π΄ΡΡΠ³ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ, ΡΡΡΠΎΠΉΡΠΈΠ²ΡΠΉ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΡΠ²Π΅Ρ ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ Π±ΡΠ» Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (100%) Π² ΡΠ»Π΅Π΄ΡΡΡΠΈΡ
ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ°Ρ
: ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ 3 (n=76), Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ 1a (n=5), Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ 1b (n=29) ΠΈ Β«Π΄ΡΡΠ³ΠΈΠΌΠΈΒ» Π³Π΅Π½ΠΎΡΠΈΠΏΠ°ΠΌΠΈ (n=6); ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΡΠΈΡΡΠΎΠ·ΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΈ (n=36) ΠΈ Ρ Π½Π΅ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ ΠΎ ΡΠΈΡΡΠΎΠ·Π΅ (n=3); ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ°Π½Π΅Π΅ (n=14); ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΠΊΠΎ-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π²ΠΈΡΡΡΠ° ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠΈΡΠΈΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° / Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (n=11); ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΡΡΠ°ΡΡΠ΅ 65 Π»Π΅Ρ (n=7) ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ, ΡΠΏΠΎΡΡΠ΅Π±Π»ΡΠ²ΡΠΈΠ΅ Π½Π°ΡΠΊΠΎΡΠΈΠΊΠΈ (n=10).ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΠΉ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π² Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π΅ Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ. ΠΠ°ΠΏΡΠΎΡΠΈΠ², ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΠΎΠ±ΡΠ΅Π΅ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΡΡ
ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ² Π½Π° Π²ΠΈΠ·ΠΈΡΠ΅ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ. ΠΠ°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ 3 Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΡ Ρ 3 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²: 2 ΡΠ»ΡΡΠ°Ρ Π»Π΅Π³ΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ (ΠΊΠ°ΡΠ΅Π»Ρ ΠΈ ΡΡΠΏΡ) ΠΈ 1 ΡΡΠΆΠ΅Π»ΡΠΉ ΡΠ»ΡΡΠ°ΠΉ, ΡΠ°ΡΡΠ΅Π½Π΅Π½Π½ΡΠΉ ΠΊΠ°ΠΊ ΡΠ΅ΡΡΠ΅Π·Π½ΠΎΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΡΠ²Π»Π΅Π½ΠΈΠ΅ (Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΡ ΡΠΈΡΡΠΎΠ·Π°). ΠΠ΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΡ ΡΠΈΡΡΠΎΠ·Π° ΠΏΡΠΈΠ²Π΅Π»Π° ΠΊ Π²ΡΠ±ΡΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΈΠ· ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠΎ ΠΌΠ½Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Ρ, Π΄Π°Π½Π½ΠΎΠ΅ ΡΠ΅ΡΡΠ΅Π·Π½ΠΎΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΡΠ²Π»Π΅Π½ΠΈΠ΅ Π½Π΅ Π±ΡΠ»ΠΎ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΠΏΡΠΈΠ΅ΠΌΠΎΠΌ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ°, Π΅Π³ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π»ΠΈ 2 ΠΌΠ΅ΡΡΡΠ° Π΅ΠΆΠ΅Π΄Π½Π΅Π²Π½ΠΎΠ³ΠΎ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ. ΠΠ· Π²ΡΠ΅Ρ
Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΠΉ, ΠΏΠΎ ΠΌΠ½Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ, ΡΠΎΠ»ΡΠΊΠΎ Π΄Π»Ρ ΡΡΠΏΠΈ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° ΡΠ²ΡΠ·Ρ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ°.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: Π΄ΠΎΠΊΠ°Π·Π°Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π»Π΅ΠΊΠ°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΈ ΠΏΠΈΠ±ΡΠ΅Π½ΡΠ°ΡΠ²ΠΈΡΠ° Π² ΡΡΡΠΈΠ½Π½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎ Π²ΡΠ΅ΠΌΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠ°ΠΌΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘, Π²ΠΊΠ»ΡΡΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ 3 ΠΈ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠΈΡΡΠΎΠ·ΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΈ. Π§Π°ΡΡΠΎΡΠ° Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ, ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π² ΡΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ, ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ ΡΠΎΠ³Π»Π°ΡΡΠ΅ΡΡΡ Ρ ΡΠ°Π½Π΅Π΅ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ. Π Π΅ΠΆΠΈΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ
ΠΎΡΠΎΡΠΎ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠ»ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ